Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

Oncogene

Volumn 32, Issue 34, 2013, Pages 4034-4042

  Sunaga, N ^a   Kaira, K ^a   Imai, H ^a   Shimizu, K ^a   Nakano, T ^a   Shames, D S ^b,c   Girard, L ^c,d   Soh, J ^d,f   Sato, M ^e   Iwasaki, Y ^a   Ishizuka, T ^a   Gazdar, A F ^d   Minna, J D ^c,d   Mori, M ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f OKAYAMA UNIVERSITY   (Japan)

Author keywords

EREG; KRAS; NSCLC; Therapeutic target

Indexed keywords

B RAF KINASE; EPIREGULIN; K RAS PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR;

ALLELE; ARTICLE; CANCER PROGNOSIS; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; WILD TYPE;

AGED; APOPTOSIS; BUTADIENES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NITRILES; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; PYRIDAZINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 84883183202     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.402     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011; 32: 703-740.
3. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299.
4. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
5. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
6. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29: 49-60.
7. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 2011; 10: 336-346.
8. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T et al. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995; 270: 7495-7500.
9. Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998; 273: 10496-10505.
10. Riese 2nd DJ, Komurasaki T, Plowman GD, Stern DF. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J Biol Chem 1998; 273: 11288-11294.
11. Toyoda H, Komurasaki T, Uchida D, Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997; 326: 69-75.
12. Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y et al. Epiregulin is upregulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000; 273: 1019-1024.
13. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227-6233.
14. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004; 64: 7813-7821.
15. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005; 65: 11478-11485.
16. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
17. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res 2008; 1: 201-207.
18. Wang X, Colby JK, Rengel RC, Fischer SM, Clinton SK, Klein RD. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune-and cell proliferation-related genes. Mol Carcinog 2009; 48: 1-13.
19. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009; 15: 4829-4237.
20. Takahashi M, Hayashi K, Yoshida K, Ohkawa Y, Komurasaki T, Kitabatake A et al. Epiregulin as a major autocrine/paracrine factor released from ERKand p38MAPK-activated vascular smooth muscle cells. Circulation 2003; 108: 2524-2529.
21. Cho MC, Choi HS, Lee S, Kim BY, Jung M, Park SN et al. Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells. Biochem Biophys Res Commun 2008; 377: 832-837.
22. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009; 4: e7464.
23. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-9383.
24. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011; 29: 3574-3579.
25. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 2000; 60: 6886-6889.
26. Lee S, Kang J, Cho M, Seo E, Choi H, Kim E et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009; 34: 161-172.
27. Chu EK, Foley JS, Cheng J, Patel AS, Drazen JM, Tschumperlin DJ. Bronchial epithelial compression regulates epidermal growth factor receptor family ligand expression in an autocrine manner. Am J Respir Cell Mol Biol 2005; 32: 373-380.
28. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119: 3000-3010.
29. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996; 24: 32-91.
30. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68: 6913-6921.
31. Draper BK, Komurasaki T, Davidson MK, Nanney LB. Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation. J Cell Biochem 2003; 89: 1126-1137.
32. Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM et al. Molecular characterization of human telomerase reverse transcriptase- immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003; 63: 1743-1747.
33. Zhao M, He HW, Sun HX, Ren KH, Shao RG. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun 2009; 387: 239-244.
34. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-770.
35. Hu K, Li SL, Gan YH, Wang CY, Yu GY. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol 2009; 45: 156-163.
36. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res 2008; 1: 156-160.
37. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
38. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493-4498.
39. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
40. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
41. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009; 4: e4576.
42. Kris M, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC). J Clin Oncol 2011; 29 (Suppl; abstract CRA7506).
43. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28: S24-S31.
44. Imai H, Sunaga N, Shimizu Y, Kakegawa S, Shimizu K, Sano T et al. Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol 2010; 23: 153-164.
45. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012; 130: 1733-1744.
46. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004; 64: 4277-4285.
47. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746-3753.